Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- US Subsidiaries of Daiichi, Sankyo to Integrate Operations
April 3, 2006
- Janus Initiates PII Trial of Topical Herpes Zoster Treatment in US
April 3, 2006
- Worldwide Production of Tamiflu Expanded to 400 Mil. Treatments: Chugai
April 3, 2006
- CytoPathfinder, Santen to Do Joint Research for Ophthalmic Drugs
April 3, 2006
- BUSINESS NEWS IN BRIEF
April 3, 2006
- PMDA to Propose Policy Regarding Int'l Joint Clinical Trials
April 3, 2006
- Dispensing Fee Revision to Hit Major Dispensing Pharmacies: JPA
April 3, 2006
- Japan Should Participate in Global Trials from an Early Stage: Mr Mori of PMDA
April 3, 2006
- JPA's Top Priority Projects Outlined by Mr Ishii
April 3, 2006
- R&D NEWS IN BRIEF
April 3, 2006
- Hodanren Submits Petition on NHI Pricing, Medical Fees
April 3, 2006
- SEMINAR
April 3, 2006
- Meeting of Prefectural Pharm. Affairs Managers
April 3, 2006
- TeGenero's Investigational Antibody Drug Causes Disaster in PI Trial
April 3, 2006
- The WHO, IFPMA to Cooperate to Combat Counterfeit Drugs
April 3, 2006
- Korosho to Standardize Package Inserts for Generics
April 3, 2006
- REGULATORY NEWS IN BRIEF
April 3, 2006
- Shift to Low-priced Drugs Could Weaken Wholesalers: FJPWA
April 3, 2006
- SELF-MEDICATION NEWS IN BRIEF
April 3, 2006
- Sales Up 9.7% in 2005 Targeting Diabetes: Novo Nordisk
March 27, 2006
ページ
Japan will overhaul its R&D tax credit regime in its FY2026 reform, introducing a new strategic category alongside existing frameworks.…
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…